Report Overview

Canada's SGLT2 Inhibitors Therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of X.X% during the forecast period.

Sodium-glucose transporters are proteins responsible for the reabsorption of glucose from kidneys. This protein family has two members: sodium-glucose cotransporter-1 (SGLT1) and sodium-glucose cotransporter-2 (SGLT2). SGLT2 is expected to reabsorb 90% of the glucose from kidneys, while SGLT1 absorbs the remaining 10%. SGLT2 inhibitors are drugs that affect the action of SGLT2 proteins, thereby reducing blood glucose levels. Hence, these are important in the treatment of type II diabetes. SGLT2 inhibitors are expected to have high consumption in the near future due to simple treatment methods and relatively better results, and preferred line of treatment for type II diabetes. Additionally, the rising prevalence of diabetes in Canada is expected to drive the global SGLT2 inhibitors market.



Market Driving and Restraining Factors

As there is a significant growth of the diabetic population, primarily type 2 diabetic patients in Canada, new innovative drugs are coming up in the market to increase access to the patients. With the increase in the diabetic population, the need and demand for diabetes drugs are expected to increase. The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drug market. However, the higher cost of SGLT2 inhibitors is acting as a restraining factor for market growth.